Close

POET Founder, Chairman and CEO Jeff Broin to Receive 2017 BIO George Washington Carver Award

BIO today announced that POET Founder, Chairman and CEO Jeff Broin will receive the 10th annual George Washington Carver Award for Innovation in Industrial Biotechnology. The award will be presented on Monday July 24, 2017, during a morning plenary session of the 2017 BIO World Congress on Industrial Biotechnology. The world’s largest industrial biotechnology and partnering event will be held July 23-26, 2017 at the Palais des congrès de Montréal in Montréal, Québec, Canada.

BIO Applauds Creation of FDA Opioid Policy Steering Committee

Washington, DC (May 24, 2017) – Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood issued the following statement regarding the announced creation of an Opioid Policy Steering Committee at the Food and Drug Administration (FDA):

Astellas Expands Advocacy Engagement with Focused Outreach

BIO Statement on President’s Proposed 2018 Budget

Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood issued the following statement in response to President Trump’s FY 2018 budget proposal.

Biotech Industry Continues Strong Growth in 2016; San Diego Setting Pace for State, Nation

Mayor Faulconer, Industry Leaders Reveal Latest Data, Including Major Economic Benefits of June BIO 2017 Convention

BIO Joins Diverse Coalition Promoting Market-Based Solutions to Address Prescription Drug Costs, Increase Patient Access and Choice

Washington, DC (May 17, 2017) – Today, the Biotechnology Innovation Organization (BIO) joins with a diverse coalition of stakeholders in endorsing a set of pro-competition,...

BIO Submits Comments Re: 340 B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties (CMP) Regulation Interim Final Rule

BIO submitted comments in response to the 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation Interim Final Rule (the "Interim Final Rule") published in the Federeal Register on March 20, 2017. In the balance of this letter, we discuss each of our concerns in detail, focusing on the need to delay the effective date of the Final Rule until HRSA can complete revisions to the Final Rule through notice-and-comment rulemaking that address: The significant burden of the “penny pricing” policy finalized in the Final Rule; The need to revise the regulatory definition of the “knowing and intentional” standard to comply with its statutory intent; and The need to revise the treatment of ceiling price calculations for newlylaunched drugs and the definition of “instances of overcharging” to mitigate the significant and undue burden these Final Rule provisions place on manufacturers.  

BIO Submits Comments to EPA Regulatory Reform Task Force

BIO submitted comments to the Environmental Protection Agency’s Regulatory Reform Task Force on Executive Order 13777 “Enforcing the Regulatory Reform Agenda.”

BIO Comment on Executive Order 13777, Enforcing the Regulatory Reform Agenda

The Biotechnology Innovation Organization’s (“BIO”) Industrial and Environmental Section (“IES”) is pleased to provide the U.S. Environmental Protection Agency (“EPA”) input to inform its Task Force evaluation of existing regulations under Executive Order 13777, “Enforcing the Regulatory Reform Agenda.”

BIO Statement on the Passing of Biotechnology Giant Henri Termeer

Termeer was a key architect in the founding of BIO, a mentor to countless entrepreneurs, executives and researchers, and passionate in his pursuit of innovative patient...